The short answer: Not much right away, although failing to pay creditors is never a good thing for a nation's creditworthiness
Coca-Cola’s North America president, Sandy Douglas, oversees a relaunch of America’s No. 1 soft drink
Four years after the Citizens United decision, out-of-state cash is flowing down to state races
Phony phone-bill items from third-party scammers date back almost 20 years
Yves Béhar's Public Office Landscape turns the workstation into a social hub
A Bluetooth-enabled sneaker from an India-based startup doubles as a fitness tracker and personal tour guide
Critics say the agency charged with keeping regulations from burdening small companies actually serves big corporate interests
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."